Condition: End Stage Kidney Disease · Sponsor: CSL Behring
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
This description comes directly from the study's public registry record.
Trial Registration Coordinator · +1 610-878-4697 · clinicaltrials@cslbehring.com
Always discuss trial participation with your own doctor first.
| Nephrology of North Alabama | Decatur, Alabama, United States | Recruiting |
| Nephrology Consultants, LLC | Huntsville, Alabama, United States | Recruiting |
| DaVita Clinical Research Montgomery | Montgomery, Alabama, United States | Recruiting |
| AKDHC Medical | Glendale, Arizona, United States | Recruiting |
| Kidney Disease Medical Group | Glendale, Arizona, United States | Recruiting |
| AKDHC Medical | Phoenix, Arizona, United States | Recruiting |
| AKDHC Medical | Tucson, Arizona, United States | Recruiting |
| Southern Arizona VA Health Care System | Tucson, Arizona, United States | Recruiting |
| National Institute of Clinical Research | Bakersfield, California, United States | Recruiting |
| Amicis Research Center | Beverly Hills, California, United States | Withdrawn |
| California Institute of Renal Research | Chula Vista, California, United States | Recruiting |
| The Medical Research Group, Inc. | Fresno, California, United States | Recruiting |
+ 536 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05485961